Tiziana Life Sciences Announces Share Acquisition by Executive Chairman

On December 19, 2025, Tiziana Life Sciences LTD announced that its Executive Chairman, Gabriele Cerrone, through an entity named Panetta Partners Limited, acquired 97,687 common shares. This acquisition brings his total shareholding to 43,374,830 common shares, representing 36.08% of the company's issued share capital. The company also provided updates on its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Foralumab is being studied for its potential in treating neuroinflammatory and neurodegenerative diseases, with ongoing trials including an Expanded Access Program for Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) and a Phase 2a trial. The intranasal delivery method is highlighted as a novel approach to immunotherapy, potentially offering improved efficacy, safety, and tolerability compared to traditional intravenous delivery.